astrazeneca glp 1 AZ to terminate once-daily cotadutide program to focus on weekly GLP-1RA co-agonist GLP-1s and more weigh in

Description

As such, payers should consider: Starting members on tailored weight loss solutions before authorizing GLP-1 treatment coverage Covering holistic programs inclusive of GLP-1 therapies Including conditional terms that provide short-term coverage for GLP-1 patients and Transition patients on to longer-term sustainable programs, such as: Newtopias GLP-1 Sustain is a habit-changing platform that ensures short-term GLP-1 benefits last through long-term change, supporting an eventual positive ROI

J Ren Nutr

Safety The most frequently reported side effects of GLP-1RAs are of gastrointestinal (GI) origin, including nausea, vomiting, diarrhoea and obstipation and may be more common in patients with higher age, lower body weight, renal impairment, and if there is a history or currently smoking (75)

All animals remained alert and responsive with no other notable changes in appearance, activity, or behavior compared to rats treated with vehicle alone

Importantly, subclinical hypothyroidism can represent an adaptive, obesity-related metabolic response, and weight loss itself is known to improve inflammatory and immune profiles